Forecasting Unanticipated Consequences of “The Sunshine Act”: Mostly Cloudy

Por Ratain, Mark J.
Publicado no J Clin Oncol (2014)

Prescribing oral chemotherapy

Por Parsad, Sandeep D, Ratain, Mark J
Publicado em 2007

Inconsistent labeling of food effect for oral agents across therapeutic areas: differences between oncology and non-oncology products

Por Kang, Soonmo Peter, Ratain, Mark J.
Publicado em 2010

Pharmacogenetics and Pharmacogenomics of Anticancer Agents

Por Huang, R. Stephanie, Ratain, Mark J.
Publicado em 2009

Might cigarettes be a “smoking gun” to reduce taxane myelotoxicity?

Por Lewis, Lionel D., Ratain, Mark J.
Publicado em 2012

Taking a Measured Approach to Toxicity Data in Phase I Oncology Clinical Trials

Por Sharma, Manish R., Ratain, Mark J.
Publicado no Clin Cancer Res (2015)

Uridine 5′-diphosphoglucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy

Por Ramírez, Jacqueline, Ratain, Mark J, Innocenti, Federico
Publicado em 2010

Inhibition of paracetamol glucuronidation by tyrosine kinase inhibitors

Por Liu, Yong, Ramírez, Jacqueline, Ratain, Mark J
Publicado em 2011

Germline pharmacogenomics in oncology: Decoding the patient for targeting therapy

Por O'Donnell, Peter H., Ratain, Mark J.
Publicado no Mol Oncol (2012)

The role of pharmacogenetics in cancer therapeutics

Por Yong, Wei Peng, Innocenti, Federico, Ratain, Mark J
Publicado em 2006

The HapMap Resource is Providing New Insights into Ourselves and its Application to Pharmacogenomics

Por Zhang, Wei, Ratain, Mark J., Dolan, M. Eileen
Publicado em 2008

CYP2D6 Genotype and Tamoxifen Activity: Understanding Interstudy Variability in Methodological Quality

Por Ratain, Mark J., Nakamura, Yusuke, Cox, Nancy J.
Publicado em 2013

Searching for Tissue-Specific Expression Pattern-Linked Nucleotides of UGT1A Isoforms

Por Zhang, Wei, Liu, Wanqing, Innocenti, Federico, Ratain, Mark J.
Publicado em 2007

Interactions between MDM2 and TP53 genetic alterations, and their impact on response to MDM2 inhibitors and other chemotherapeutic drugs in cancer cells

Por Liu, Wanqing, He, Lijun, Ramírez, Jacqueline, Ratain, Mark J
Publicado em 2009

Comparison of the Drug-Drug Interactions Potential of Erlotinib and Gefitinib via Inhibition of UDP-Glucuronosyltransferases

Por Liu, Yong, Ramírez, Jacqueline, House, Larry, Ratain, Mark J.
Publicado em 2010

The UGT1A1*28 Polymorphism Correlates with Erlotinib's Effect on SN-38 Glucuronidation

Por Liu, Yong, Ramírez, Jacqueline, House, Larry, Ratain, Mark J.
Publicado em 2010

Randomized Phase II Trials: A Long-term Investment With Promising Returns

Por Sharma, Manish R., Stadler, Walter M., Ratain, Mark J.
Publicado em 2011

Genome-wide identification of genetic determinants for the cytotoxicity of perifosine

Por Zhang, Wei, Liu, Wanqing, Poradosu, Enrique, Ratain, Mark J
Publicado em 2008

Models of Excellence: Improving Oncology Drug Development

Por Sharma, Manish R., Maitland, Michael L., Ratain, Mark J.
Publicado em 2012

The Outlier in All of Us: Why Implementing Pharmacogenomics Could Matter for Everyone

Por O’Donnell, Peter H., Danahey, Keith, Ratain, Mark J.
Publicado no Clin Pharmacol Ther (2016)